Elevated circulating DcR3 levels associated with interstitial lung disease and disease progression in systemic sclerosis
Deucravacitinib demonstrated sustained efficacy and favourable safety through 52 weeks in patients with active psoriatic arthritis
Enpatoran showed significant dose-dependent reduction in cutaneous lupus disease activity in phase 2 WILLOW trial
Baseline CRP levels were associated with greater treatment retention for TNF inhibitors but not IL-17 inhibitors in axial spondyloarthritis
